Candriam SCA’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-159,054
| Closed | -$3.48M | – | 681 |
|
|
2025
Q1 | $3.48M | Sell |
159,054
-380,548
| -71% | -$10.5M | 0.02% | 400 |
|
|
2024
Q4 | $17.2M | Sell |
539,602
-140,456
| -21% | -$4.22M | 0.1% | 189 |
|
|
2024
Q3 | $19.6M | Buy |
680,058
+137,023
| +25% | +$5.07M | 0.11% | 182 |
|
|
2024
Q2 | $20.8M | Sell |
543,035
-41,890
| -7% | -$1.9M | 0.13% | 162 |
|
|
2024
Q1 | $34.4M | Buy |
584,925
+247,418
| +73% | +$15.8M | 0.22% | 110 |
|
|
2023
Q4 | $20.2M | Buy |
337,507
+11,000
| +3% | +$558K | 0.14% | 158 |
|
|
2023
Q3 | $12.4M | Hold |
326,507
| – | – | 0.09% | 204 |
|
|
2023
Q2 | $29.7M | Sell |
326,507
-117,000
| -26% | -$10.1M | 0.22% | 119 |
|
|
2023
Q1 | $26.9M | Buy |
443,507
+165,000
| +59% | +$9.52M | 0.19% | 133 |
|
|
2022
Q4 | $14.4M | Sell |
278,507
-65,000
| -19% | -$3.45M | 0.1% | 211 |
|
|
2022
Q3 | $23.5M | Sell |
343,507
-271,950
| -44% | -$16.1M | 0.17% | 139 |
|
|
2022
Q2 | $27.8M | Buy |
615,457
+149,362
| +32% | +$6.81M | 0.23% | 104 |
|
|
2022
Q1 | $23.7M | Sell |
466,095
-228,330
| -33% | -$10.1M | 0.16% | 141 |
|
|
2021
Q4 | $32.8M | Buy |
694,425
+439,395
| +172% | +$17.3M | 0.21% | 123 |
|
|
2021
Q3 | $8.4M | Sell |
255,030
-62,285
| -20% | -$3.5M | 0.06% | 305 |
|
|
2021
Q2 | $20.1M | Sell |
317,315
-238,059
| -43% | -$12.3M | 0.14% | 174 |
|
|
2021
Q1 | $30.5M | Hold |
555,374
| – | – | 0.25% | 103 |
|
|
2020
Q4 | $31.8M | Sell |
555,374
-593,491
| -52% | -$25.1M | 0.25% | 103 |
|
|
2020
Q3 | $34.7M | Sell |
1,148,865
-61,533
| -5% | -$1.84M | 0.33% | 69 |
|
|
2020
Q2 | $39.5M | Buy |
1,210,398
+818,198
| +209% | +$26.3M | 0.42% | 50 |
|
|
2020
Q1 | $11.7M | Hold |
392,200
| – | – | 0.13% | 182 |
|
|
2019
Q4 | $12M | Sell |
392,200
-42,500
| -10% | -$1.18M | 0.13% | 184 |
|
|
2019
Q3 | $10.5M | Sell |
434,700
-93,000
| -18% | -$2.56M | 0.14% | 175 |
|
|
2019
Q2 | $13.3M | Hold |
527,700
| – | – | 0.17% | 144 |
|
|
2019
Q1 | $10.3M | Hold |
527,700
| – | – | 0.13% | 181 |
|
|
2018
Q4 | $6.96M | Buy |
527,700
+12,000
| +2% | +$184K | 0.11% | 220 |
|
|
2018
Q3 | $9.17M | Buy |
515,700
+275,700
| +115% | +$5.1M | 0.12% | 202 |
|
|
2018
Q2 | $5.28M | Buy |
240,000
+116,000
| +94% | +$2.67M | 0.08% | 285 |
|
|
2018
Q1 | $2.74M | Buy |
124,000
+7,000
| +6% | +$138K | 0.05% | 411 |
|
|
2017
Q4 | $2.54M | Buy |
+117,000
| New | +$1.72M | 0.04% | 410 |
|
Other funds holding APLS
ACA
EC
DTC
Candriam SCA's APLS Position: Q2 2025 in Review
Candriam SCA sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 159,054 shares — an estimated $3.48M sold.
Candriam SCA first reported a position in APLS in Q4 2017 and held it in 30 quarters. The position peaked at $39.5M in Q2 2020. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.
- Candriam SCA reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Candriam SCA sold 159,054 Apellis Pharmaceuticals shares in Q2 2025, an estimated $3.48M.
- Candriam SCA first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 30 quarters.
- Candriam SCA's Apellis Pharmaceuticals position peaked at $39.5M in Q2 2020.
- 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.
Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.